117 related articles for article (PubMed ID: 9660347)
1. SEC going after insider trading based on medical research results. Securities Exchange Commission.
Skolnick AA
JAMA; 1998 Jul; 280(1):10-1. PubMed ID: 9660347
[No Abstract] [Full Text] [Related]
2. SEC slaps another researcher for insider trading. Securities and Exchange Commission.
Skolnick AA
JAMA; 1998 Jul; 280(2):124. PubMed ID: 9669773
[No Abstract] [Full Text] [Related]
3. New SEC regulations could hinder biotech investment. US Securities and Exchange Commission.
Bouchie A
Nat Biotechnol; 2002 Jul; 20(7):639-40. PubMed ID: 12089533
[No Abstract] [Full Text] [Related]
4. Biomedical research and insider trading.
Ferguson JR
N Engl J Med; 1997 Aug; 337(9):631-4. PubMed ID: 9271488
[No Abstract] [Full Text] [Related]
5. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
Whitener MD
Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
[No Abstract] [Full Text] [Related]
6. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
7. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
8. In need of treatment? Merger control, pharmaceutical innovation, and consumer welfare.
Ben-Asher D; Juris M
J Leg Med; 2000 Sep; 21(3):271-349. PubMed ID: 11055154
[No Abstract] [Full Text] [Related]
9. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
10. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
11. AstraZeneca must pay €52.5m fine for anticompetitive tactics, rules European court.
Hawkes N
BMJ; 2012 Dec; 345():e8396. PubMed ID: 23230222
[No Abstract] [Full Text] [Related]
12. Hoechst plans divestitures to gain FTC nod.
Scott L
Mod Healthc; 1995 Sep; 25(39):32. PubMed ID: 10151416
[No Abstract] [Full Text] [Related]
13. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
14. Wall Street and clinical trials.
Steinbrook R
N Engl J Med; 2005 Sep; 353(11):1091-3. PubMed ID: 16162879
[No Abstract] [Full Text] [Related]
15. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
Steinhauer EH
Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
[No Abstract] [Full Text] [Related]
16. Bundling patented drugs and medical services: an antitrust analysis.
Hurwitz MA
Spec Law Dig Health Care Law; 1992 Jan; (155):7-39. PubMed ID: 10115664
[No Abstract] [Full Text] [Related]
17. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
18. Pharmacies take uniform price demands to court.
Moskowitz DB
J Am Health Policy; 1994; 4(4):24-7. PubMed ID: 10136676
[No Abstract] [Full Text] [Related]
19. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
Zain S
Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
[No Abstract] [Full Text] [Related]
20. Will antitrust cops bust billion-dollar drug deals?
Barnett AA
J Am Health Care; 1994; 4(5):5-7. PubMed ID: 10142816
[No Abstract] [Full Text] [Related]
[Next] [New Search]
